In the wake of Pfizer Inc.’s announcement one day prior for a late November launch of Inflectra, its biosimilar of Remicade, Johnson & Johnson execs calmly reiterated during its third-quarter earnings call that its plans for biosimilar competition to its top-seller remain largely unchanged, indicating no additional significant discounting should be necessary in what already is a competitively priced therapeutic space.
The pillars of J&J’s strategy to hold off sales erosion of Remicade (infliximab) rely on the lack of interchangeability for biosimilars and an entrenched clinician and patient base; differentiation from the Pfizer/Celltrion Inc
“We are confident that we have a strong plan [to offset biosimilar competition,]” Worldwide Chairman-Pharmaceuticals Joaquin Duato told Oct. 18 earnings call. “There's no interchangeability
